MAR 23, 2020 12:16 PM PDT

An Alternative Use for Common Kidney Cancer Drug to Fight Against Epithelial Ovarian Cancer

WRITTEN BY: Jasper Cantrell

Epithelial ovarian cancer, or EOC, is one of the leading causes of cancer related death in women. The primary treatments for EOC revolve around surgical removal of the tumor followed by administration of one or more chemotherapeutic drugs.

One of the chemotherapy targets is the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase family. VEGF is important for angiogenesis and has been shown to stimulate cellular migration in vitro. Overexpression has been linked to progression in ovarian cancers.  One of a new generation of drugs targeting this kinase is axitinib. Axitinib is a small molecule drug that inhibits VEGFR tyrosine kinases 1, 2, and 3. Shown previously to potentially prevent angiogenesis and promote apoptosis in cancer cells, it is currently a treatment for renal cell carcinomas. Phase 2 trials with axitinib on a variety of solid tumors have also shown positive results. E Sun Paik, Tae-Hyun Kim, and Young Jae Cho proceeded to conduct pre-clinical testing on axitinib’s effectiveness against epithelial ovarian cancer, saying “We hypothesize that axitinib inhibits EOC cells by targeting multiple pathways including angiogenesis, AKT, and ERK phosphorylation”.

Starting with in vitro studies, the group began by testing axitinib’s anti-cancer activity on a set of EOC cell lines including A2780, RMG1, HeyA8, and its drug resistant variant HeyA8-MDR. Measuring active Caspase-3 activity, the group found that axitinib seemed to induce apoptosis in a dose dependent manner as well as decrease cell viability in all cell lines. Following up by measuring levels of VEGFR, and the phosphorylated versions of ERK and AKT, it was found that the all lines except HeyA8-MDR had decreased levels of p-VEGFR, p-ERK, and p-AKT inferring decreased cellular proliferation. Follow up cell migration assays affirmed the VEGFR test, showing that A2780 and HeyA8 had decreased migration abilities where HeyA8-MDR had no significant change compared to controls. These in vitro assays seem to point to axitinib having anti-cancer activity against EOC lines, except in the case of drug resistant variants.

The group then began in vivo testing, implanting EOC lines A2780, RMG1, and HeyA8-MDR into mice and treating them with axitinib. It was found that after 7 days, tumors from A2780 and RMG1 had halved in weight compared to controls, while HeyA8-MDR did not show significant changes compared to controls. They then confirmed the previous in vitro cell proliferation and apoptosis results using Ki-67 staining to measure proliferation and TUNEL assays to measure apoptosis showing again that the drug resistant HeyA8-MDR showed no change with axtinib treatment.

The group continued the testing, using three patient derived xenografts (PDX), with one heavily pre-treated and platinum resistant carcinoma model. Upon treatment with axitinib, only the drug resistant model did not respond to axitinib, while the others having significantly decreased tumor weight. This was confirmed again with Ki-67 staining and TUNEL assays agreeing with both the in vitro and in vivo tests.

The group summed up their results by concluding that the “anti-tumor effects of axitinib as a single agent were significant only in drug-sensitive EOC models but were not remarkable in drug-resistant EOC cell line xenograft or PDX models”. Axitinib is already an FDA approved treatment for renal cell carcinomas, and this work shows it might also be effective in the treatment of epithelial ovarian cancer.

Sources: Scientific Reports, OncLiveTV

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
NOV 05, 2020
Immunology
Awakening Ancient DNA to Kill Cancer
NOV 05, 2020
Awakening Ancient DNA to Kill Cancer
In a recent study published in Nature, scientists from the University of Toronto described the discovery of ancient DNA ...
NOV 16, 2020
Cancer
Fingerprinting Ginger Extracts and Testing Their Anti-Cancer Abilities
NOV 16, 2020
Fingerprinting Ginger Extracts and Testing Their Anti-Cancer Abilities
Modern medicine relies on careful study and isolation of compounds or proteins, but many studies point to natural herbal ...
DEC 07, 2020
Cancer
Black women with breast cancer have higher rates of mortality and comorbidities
DEC 07, 2020
Black women with breast cancer have higher rates of mortality and comorbidities
New research published today the American Cancer Society’s peer-reviewed journal, Cancer, looks at the mortality r ...
DEC 08, 2020
Cancer
Stress hormones interrupt tumor cells' hibernation
DEC 08, 2020
Stress hormones interrupt tumor cells' hibernation
A new study published in Science Translational Medicine suggests that the hormones released from stress could “rea ...
DEC 21, 2020
Cancer
Cancer survivors have a higher risk of developing subsequent primary cancers
DEC 21, 2020
Cancer survivors have a higher risk of developing subsequent primary cancers
New research published in JAMA has found that cancer survivors have a higher risk of developing subsequent primary cance ...
JAN 27, 2021
Cancer
Does intermittent fasting reduce the risk of postmenopausal breast cancer?
JAN 27, 2021
Does intermittent fasting reduce the risk of postmenopausal breast cancer?
New research in mouse models suggests that intermittent fasting could reduce the risk of metastasis of breast cancer tum ...
Loading Comments...